Kristin Yarema
Known title: Chief Executive OfficerCIK: 0001803794
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Transaction History
| IMA | ▲ Buy | Grant | 254,800 | $0 | 8/14/2026 | View on chart |
| IMA | ▲ Buy | Option Exercise | 38,376 | $0 | 7/25/2026 | View on chart |
| IMA | ▼ Sell | Other | 115,129 | $0 | 7/25/2026 | View on chart |
| IMA | ▲ Buy | Grant | 85,400 | $0 | 3/16/2026 | View on chart |
| ATRA | ▲ Buy | Grant | 45,533 | $0 | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule
ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.